InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (2 ops.)
Insider track record
CFODisclosed buys
3
Disclosed sells
2
T+90 hit rate
38%
T+90 mean return
-31.6%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Taylor Beth, Chief Financial Officer. Officer active across 2 companies, notably Inotiv, Inc.. In total, 18 disclosures have been published. Split: 3 buys · 2 sells. Total volume traded: €210k. Activity tracked since 7 May 2021. The latest transaction was disclosed on 14 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations18 total
40,000 shares0Common StockSEC:0001062993-25-005698:0
4,370 shares@ US$4.00618.0% of flowCommon StockSEC:0001062993-25-003060:0
2,054 shares@ US$4.4654.2% of flowCommon StockSEC:0001062993-25-001624:0
20,000 shares0Common StockSEC:0001062993-24-015122:0
5,000 shares0Common StockSEC:0001062993-23-004285:0
5,917 shares0Common StockSEC:0001062993-23-001180:0
5,000 shares@ US$23.07150.20% mcap55.1% of flowCommon SharesSEC:0001179110-22-001480:0
Ideal exit: 15 Nov 2022 (T+270)
40,000 shares0Common SharesSEC:0001179110-22-001378:0
214 shares0Common SharesSEC:0001179110-21-011144
214 shares0Common SharesSEC:0001179110-21-011144:0
1,332 shares0Common SharesSEC:0001179110-21-009623:0
1,332 shares0Common SharesSEC:0001179110-21-009623
2,154 shares@ US$23.1422.4% of flowCommon SharesSEC:0001179110-21-005394
Ideal exit: 7 Feb 2022 (T+270)
2,154 shares@ US$23.140.083% mcap22.4% of flowCommon SharesSEC:0001179110-21-005394:0
Ideal exit: 7 Feb 2022 (T+270)
880 shares0Common SharesSEC:0001179110-21-005180:0
880 shares0Common SharesSEC:0001179110-21-005180
525 sharesCommon StockSEC:0001144204-16-079693:1
3,750 sharesCommon StockSEC:0001144204-16-079693:0
18 of 18 declarations
About Taylor Beth
Beth Taylor is the Vice President of Finance and Chief Financial Officer at Inotiv, Inc. She oversees the company's financial functions, including financial planning, risk management, and financial reporting. With significant experience in the life sciences sector, she plays a crucial role in financial strategy and overall company performance. Her expertise is essential for ensuring transparency and compliance in financial operations.
